Results 221 to 230 of about 164,703 (282)

Psychosocial vulnerabilities and loss to follow‐up in people living with HIV in France

open access: yesHIV Medicine, EarlyView.
Abstract Background Migration status is consistently associated with a higher risk of loss to follow‐up (LTFU). We investigated how sex, sexual orientation and social vulnerabilities affect the association between migration status and LTFU for hospital care in people living with HIV, using data from the ANRS CO9‐COPANA cohort linked to the nationwide ...
Charlène Mafuta   +8 more
wiley   +1 more source

Real‐world evidence for the efficacy and tolerability of an isobutylamido‐thiazolyl‐resorcinol (Thiamidol)‐containing skincare regimen on facial hyperpigmentation and overall skin appearance: A multi‐centre study in 11 European countries

open access: yesInternational Journal of Cosmetic Science, EarlyView.
A Thiamidol‐containing skincare regimen showed significant improvement in facial hyperpigmentation in a real‐world study across 11 European countries. The treatment led to a significant reduction in mMASI scores, enhanced overall skin condition and demonstrated high tolerability.
B. Schuster   +12 more
wiley   +1 more source

Deep Learning Models for Detection of Periapical Radiolucent Lesions on Panoramic Radiographs: A Systematic Review and Meta‐Analysis

open access: yesInternational Endodontic Journal, EarlyView.
ABSTRACT Background Panoramic radiographs are used routinely to screen dental conditions and treatment patterns. Recently, numerous studies have suggested that deep learning (DL) models can be utilized for analysing panoramic radiographs. Objective This review aimed to evaluate the accuracy of DL models in detecting periapical radiolucent lesions (PRLs)
Ibrahim Ali Ahmad   +3 more
wiley   +1 more source

Superior Clinical and Economic Value of IL‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis

open access: yesInternational Journal of Dermatology, EarlyView.
A bicentric retrospective real‐world study (N = 616) comparing IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) with adalimumab biosimilars in moderate‐to‐severe plaque psoriasis. It presents PASI90 response at Weeks 16 and 52, NNT, and cost‐effectiveness (incremental cost per responder, CE plane, CEAC/CEAF).
Gennaro Marco Falco   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy